New formulation improves safety for patients.
Previously approved for IV infusion.
Fourth indication expansion for the 2009 drug.
Reduces risk for heart failure and cardiovascular disease hospitalizations.
Drug able to treat 18,000 people will cost over $300k per year.
Available for prescribing starting January 2020
First approved in 2018 for patients 12 years of age and older.
Originally approved in 1995 for use in adults only.
Administered via a once-daily transdermal patch.
New CGM eliminates fingersticks, introduces new data presentation.